Study conducted under U.S. FDA Investigational New Drug (IND) authorization by Dr. Anthony Back at the University of WashingtonSecond psilocybin session showed meaningful improvements in anxiety, depression, and overall psychological outcomes, with effects lasting up…

Three new license agreements signed and two research shipments completed in March 2026, spanning institutions in Australia, the United Kingdom, and CanadaToronto, Ontario–(Newsfile Corp. – April 7, 2026) – Red Light Holland Corp. (CSE: TRIP)…

Toronto, Ontario–(Newsfile Corp. – April 1, 2026) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") today announced that, through Filament Health Corp. ("Filament"), it will support the…

Toronto, Ontario–(Newsfile Corp. – March 23, 2026) –  Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Filament Health Corp. (OTC: FLHLF) ("Filament") today announced that, further to…

AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industryToronto, Ontario and Arlington, Massachusetts–(Newsfile Corp. – March 18, 2026) -…